Akros   Report issue

For profit Phase 1 Phase 2 Phase 4
Founded: Durham NC United States (2015)
Status: No NME R&D (2015)

Organization Overview

First Clinical Trial
2015
NCT00688896
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2023

Timeline

NOW
  • Now

Alternative names

AKROS Global Health | Akros Pharma Inc.

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Arthritis (Phase 2)

Arthritis, Rheumatoid (Phase 2)

Diabetes Mellitus (Phase 2)

Diabetes Mellitus, Type 2 (Phase 2)

Dyslipidemias (Phase 2)

Familial Primary Pulmonary Hypertension (Phase 2)

Hepatitis (Phase 1)

Hepatitis A (Phase 1)

Hepatitis C (Phase 1)

Hyperlipidemias (Phase 2)

Hyperlipoproteinemias (Phase 2)

Hyperlipoproteinemia Type II (Phase 2)

Hypertension (Phase 2)

Kidney Diseases (Phase 1)

Kidney Failure, Chronic (Phase 1)

Malaria (Phase 4)

Psoriasis (Phase 2)

Renal Insufficiency, Chronic (Phase 1)

Skin Diseases (Phase 2)

Virus Diseases (Phase 1)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 25
  • # of Trial APIs: 21